Can a serum plus a red light cap regrow hair?
NCT ID NCT07810504
First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time
Summary
Researchers are testing whether a scalp-stimulating serum and a red light therapy cap, used alone or together, improve hair growth in women with female pattern hair loss. Forty women aged 35 to 55 apply the serum daily and wear the light cap at home for six months. The study measures changes in hair density, thickness, and the ratio of thick to thin hairs, along with patient satisfaction and side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- KeraFactor scalp-stimulating serum and the Revian Red LED light cap, tested alone and together
- What this could lead to
- If the combination works, it could offer women with pattern hair loss a non-drug option that pairs a topical serum with a home light device.
- What could go wrong
- The trial is small, with 40 women, and runs for six months, so any hair changes may be modest or fade. Light and serum treatments often help some people and not others, and results may not hold for different ages or hair types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
35 to 55 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteriaz: * Female participants aged 35 to 55 years, inclusive. * Clinically diagnosed with androgenic alopecia. * Fitzpatrick Skin Types I-VI. * Willingness to undergo baseline laboratory screening, including CBC, TSH, iron/TIBC, 25-hydroxyvitamin D, ferritin, free testosterone, total testosterone, estradiol (E2), and FSH, to confirm eligibility and stratification status. * Generally healthy individuals with no significant dermatological conditions affecting the scalp, such as eczema, psoriasis, or folliculitis, that could interfere with treatment assessment. * Willingness to maintain a consistent hair care routine and refrain from new hair treatments, supplements, or grooming practices that could confound study results. * Willingness and ability to provide recent laboratory results to establish baseline metabolic parameters. * Participants must have a smartphone or tablet that operates on iOS version 11.0 or higher and/or Android 9.0 or higher, access to the Apple App Store or Google Play to download the REVIAN app, and internet or wireless network connectivity. * Commitment to avoid hair dryer use for at least 48 hours before and after each office visit. * Commitment to avoid hair extensions for at least 6 months prior to and throughout the study duration. * Ability and willingness to adhere to the study protocol, including scheduled visits and assessments. * Willingness to allow trichoscopic and photographic documentation of the scalp and hair. * Ability and willingness to provide written informed consent after being fully informed about the study's nature, purpose, procedures, potential risks, and benefits. Exclusion Criteria: * Presence of autoimmune or pathologic causes of hair loss, such as alopecia areata or lichen planus. * Active scalp disorders or infections, such as eczema, psoriasis, seborrheic dermatitis, or folliculitis. * Clinically significant abnormalities in baseline screening labs, including CBC, TSH, iron/TIBC, 25-hydroxyvitamin D, ferritin, free testosterone, total testosterone, E2, and FSH, that fall outside satisfactory ranges for hair growth or indicate an underlying medical pathology, such as iron deficiency anemia or thyroid dysfunction. * History of hypersensitivity to any components of KeraFactor scalp-stimulating solution. * Presence of a medical condition that makes the skin sensitive to sun or light, or use of photosensitizing medications, shampoos, lotions, or other therapies that sensitize the skin to light. * Medical conditions or medications known to significantly affect hair growth, including uncontrolled thyroid disorders, anemia, cancer, chemotherapy, spironolactone, 5-alpha-reductase inhibitors, or cyproterone. * Active use of GLP-1 receptor agonists, such as Ozempic, Wegovy, Mounjaro, Zepbound, or similar medications. * Active use of topical treatments for hair regrowth, such as minoxidil or finasteride. * Pregnant, breastfeeding, or planning to become pregnant during the study. * Unrealistic expectations or psychological conditions that may impact study compliance or satisfaction. * Continual use of red-light or low-level laser therapy outside of study requirements. * Recent initiation of topical hair regrowth treatments, such as minoxidil or finasteride. * Continual use of minoxidil, finasteride, or other hair regrowth treatments. * Any active cancer or cancer diagnosis. * Active smoking habit. * History of hair transplant procedures. * Significant scalp scarring or structural anomalies in treatment zones. * Recent major surgeries or medical interventions within the last 3 months. * History of prolonged or repeated mechanical tension on the hair or scalp, such as tight hairstyles contributing to traction alopecia.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Androgenic alopecia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
K. Kay Durairaj, M.D., A Medical Corp.
RECRUITINGPasadena, California, 91105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria supplement tested against chemo hair loss
- Can grape seed and green tea extracts turn the tide on baldness?
- A new serum aims to thicken Hair—Will it beat minoxidil?
- A daily capsule might turn back the clock on skin and hair aging
- A tiny drop of blood might be enough: study tests fingerstick accuracy
- Can a daily capsule thicken thinning hair? a trial puts three doses to the test